# Dawood Darbar

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 174 papers | 10,174 citations | 51 h-index | 99 g-index |
| 201 ext. papers | 12,586 ext. citations | 8.3 avg, IF | 5.55 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 174 | 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology*, **2013**, 61, e6-75 | 15.1 | 602 |
| 173 | Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nature Genetics*, **2012**, 44, 670-5 | 36.3 | 429 |
| 172 | 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation*, **2013**, 127, e283-352 | 16.7 | 393 |
| 171 | Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. *Circulation*, **2009**, 119, 606-18 | 16.7 | 378 |
| 170 | A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. *Nature Genetics*, **2009**, 41, 876-8 | 36.3 | 365 |
| 169 | Common variants in KCNN3 are associated with lone atrial fibrillation. *Nature Genetics*, **2010**, 42, 240-4 | 36.3 | 362 |
| 168 | Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. *Circulation*, **2008**, 117, 1255-60 | 16.7 | 308 |
| 167 | Drug-induced long QT syndrome. *Pharmacological Reviews*, **2010**, 62, 760-81 | 22.5 | 296 |
| 166 | Multi-ethnic genome-wide association study for atrial fibrillation. *Nature Genetics*, **2018**, 50, 1225-1233 | 36.3 | 277 |
| 165 | 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, **2012**, 60, 1297-313 | 15.1 | 273 |
| 164 | Familial atrial fibrillation is a genetically heterogeneous disorder. *Journal of the American College of Cardiology*, **2003**, 41, 2185-92 | 15.1 | 273 |
| 163 | Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature*, **2021**, 590, 290-299 | 50.4 | 268 |
| 162 | 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. *Circulation*, **2012**, 126, 1784-800 | 16.7 | 250 |
| 161 | Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. *Circulation*, **2008**, 117, 1927-35 | 16.7 | 245 |
| 160 | Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. *New England Journal of Medicine*, **2008**, 359, 158-65 | 59.2 | 236 |
| 159 | A rare variant in MYH6 is associated with high risk of sick sinus syndrome. *Nature Genetics*, **2011**, 43, 316-20 | 36.3 | 228 |
| 158 | Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. *Nature Genetics*, **2013**, 45, 621-31 | 36.3 | 219 |

| | | | |
|---|---|---|---|
| 157 | Role of inflammation and oxidative stress in atrial fibrillation. *Heart Rhythm*, **2010**, 7, 438-44 | 6.7 | 213 |
| 156 | Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. *Nature Genetics*, **2017**, 49, 946-952 | 36.3 | 176 |
| 155 | 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. *Journal of Thoracic and Cardiovascular Surgery*, **2014**, 148, e153-93 | 4.5 | 170 |
| 154 | Mutations in sodium channel 1- and 2-subunits associated with atrial fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 268-75 | 6.4 | 169 |
| 153 | Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. *European Heart Journal*, **2009**, 30, 813-9 | 9.5 | 165 |
| 152 | Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. *Circulation*, **2014**, 130, 1225-35 | 16.7 | 143 |
| 151 | Inherited causes of clonal haematopoiesis in 97,691 whole genomes. *Nature*, **2020**, 586, 763-768 | 50.4 | 127 |
| 150 | Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. *American Journal of Cardiology*, **1996**, 78, 284-7 | 3 | 107 |
| 149 | Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. *American Journal of Cardiology*, **2012**, 110, 369-72 | 3 | 103 |
| 148 | The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. *Clinical Research in Cardiology*, **2015**, 104, 871-6 | 6.1 | 96 |
| 147 | Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. *Journal of the American College of Cardiology*, **2012**, 60, 539-45 | 15.1 | 93 |
| 146 | Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. *Cardiovascular Research*, **2015**, 106, 520-9 | 9.9 | 86 |
| 145 | A KCNJ8 mutation associated with early repolarization and atrial fibrillation. *Europace*, **2012**, 14, 1428-32 | 3.9 | 84 |
| 144 | Unmasking of brugada syndrome by lithium. *Circulation*, **2005**, 112, 1527-31 | 16.7 | 84 |
| 143 | Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. *Circulation: Cardiovascular Genetics*, **2009**, 2, 499-506 | | 79 |
| 142 | Atrial Fibrillation Is an Independent Predictor of Mortality in Critically Ill Patients. *Critical Care Medicine*, **2015**, 43, 2104-11 | 1.4 | 77 |
| 141 | Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. *Heart Rhythm*, **2007**, 4, 743-9 | 6.7 | 77 |
| 140 | Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2010**, 48, 181-90 | 5.8 | 76 |

| | | | |
|---|---|---|---|
| 139 | Exaggerated QT prolongation after cardioversion of atrial fibrillation. *Journal of the American College of Cardiology*, **1999**, 34, 396-401 | 15.1 | 76 |
| 138 | Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. *JAMA - Journal of the American Medical Association*, **2018**, 320, 2354-2364 | 27.4 | 75 |
| 137 | Voltage-gated sodium channels: biophysics, pharmacology, and related channelopathies. *Frontiers in Pharmacology*, **2012**, 3, 124 | 5.6 | 72 |
| 136 | Common genetic variants and response to atrial fibrillation ablation. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 296-302 | 6.4 | 70 |
| 135 | Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease. *BMJ: British Medical Journal*, **1996**, 312, 874-8; discussion 878-9 | | 70 |
| 134 | Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. *Heart Rhythm*, **2013**, 10, 849-55 | 6.7 | 67 |
| 133 | Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. *Journal of the American College of Cardiology*, **2012**, 60, 1173-81 | 15.1 | 65 |
| 132 | A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. *Journal of the American College of Cardiology*, **2012**, 59, 49-56 | 15.1 | 64 |
| 131 | P wave signal-averaged electrocardiography to identify risk for atrial fibrillation. *PACE - Pacing and Clinical Electrophysiology*, **2002**, 25, 1447-53 | 1.6 | 63 |
| 130 | Genetic mechanisms of atrial fibrillation: impact on response to treatment. *Nature Reviews Cardiology*, **2013**, 10, 317-29 | 14.8 | 60 |
| 129 | Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. *Heart Rhythm*, **2010**, 7, 1246-52 | 6.7 | 58 |
| 128 | Genetic Risk Prediction of Atrial Fibrillation. *Circulation*, **2017**, 135, 1311-1320 | 16.7 | 56 |
| 127 | Effect of Peripheral Arterial Disease in Patients Undergoing Percutaneous Coronary Intervention With Intracoronary Stents. *Mayo Clinic Proceedings*, **2004**, 79, 1113-1118 | 6.4 | 53 |
| 126 | A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation. *Annals of Emergency Medicine*, **2011**, 57, 1-12 | 2.1 | 51 |
| 125 | Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. *Journal of the American College of Cardiology*, **2008**, 51, 1083-9 | 15.1 | 51 |
| 124 | Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. *American Journal of Cardiology*, **2013**, 111, 368-73 | 3 | 48 |
| 123 | 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. *Journal of Thoracic and Cardiovascular Surgery*, **2014**, 148, 772-91 | 1.5 | 47 |
| 122 | Ictal asystole and ictal syncope: insights into clinical management. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 159-64 | 6.4 | 46 |

| | | | |
|---|---|---|---|
| 121 | SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. *Cardiovascular Research*, **2014**, 104, 355-63 | 9.9 | 46 |
| 120 | A Missense Variant in PLEC Increases Risk of Atrial Fibrillation. *Journal of the American College of Cardiology*, **2017**, 70, 2157-2168 | 15.1 | 43 |
| 119 | Effect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillation. *American Journal of Cardiology*, **2015**, 115, 196-201 | 3 | 42 |
| 118 | Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. *American Journal of Cardiology*, **1996**, 77, 1351-5 | 3 | 42 |
| 117 | Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts. *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 313-20 | 6.4 | 40 |
| 116 | Differential impact of race and risk factors on incidence of atrial fibrillation. *American Heart Journal* , **2011**, 162, 31-7 | 4.9 | 39 |
| 115 | Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. *Journal of the American College of Cardiology*, **2008**, 51, 836-42 | 15.1 | 38 |
| 114 | Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: wide spectrum of disease in mutation carriers within a family. *Heart Rhythm*, **2006**, 3, 939-44 | 6.7 | 37 |
| 113 | Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study. *American Journal of Cardiology*, **2012**, 110, 1637-42 | 3 | 35 |
| 112 | Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. *DMM Disease Models and Mechanisms*, **2013**, 6, 332-41 | 4.1 | 35 |
| 111 | Tremor-induced ECG artifact mimicking ventricular tachycardia. *Circulation*, **2000**, 102, 1337-8 | 16.7 | 35 |
| 110 | Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. *PLoS ONE*, **2012**, 7, e32338 | 3.7 | 33 |
| 109 | Dietary salt increases first-pass elimination of oral quinidine. *Clinical Pharmacology and Therapeutics*, **1997**, 61, 292-300 | 6.1 | 32 |
| 108 | Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. *JAMA Cardiology*, **2016**, 1, 1007-1013 | 16.2 | 32 |
| 107 | Electrophysiologic Characterization of Calcium Handling in Human Induced Pluripotent Stem Cell-Derived Atrial Cardiomyocytes. *Stem Cell Reports*, **2018**, 10, 1867-1878 | 8 | 31 |
| 106 | Whole-exome sequencing in familial atrial fibrillation. *European Heart Journal*, **2014**, 35, 2477-83 | 9.5 | 30 |
| 105 | 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, e127-45 | 1.5 | 29 |
| 104 | Modulation by dietary salt of verapamil disposition in humans. *Circulation*, **1998**, 98, 2702-8 | 16.7 | 28 |

| | | | |
|---|---|---|---|
| 103 | Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. *Heart Rhythm*, **2005**, 2, 544-9 | 6.7 | 27 |
| 102 | Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. *American Journal of Cardiology*, **1996**, 78, 736-40 | 3 | 25 |
| 101 | Genetic and clinical risk prediction model for postoperative atrial fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2015**, 8, 25-31 | 6.4 | 24 |
| 100 | Genetics of atrial fibrillation: rare mutations, common polymorphisms, and clinical relevance. *Heart Rhythm*, **2008**, 5, 483-6 | 6.7 | 23 |
| 99 | Risk factors for bradycardia requiring pacemaker implantation in patients with atrial fibrillation. *American Journal of Cardiology*, **2012**, 110, 1315-21 | 3 | 22 |
| 98 | Coding variants in and increase risk of atrial fibrillation. *Communications Biology*, **2018**, 1, 68 | 6.7 | 21 |
| 97 | Pharmacogenetics of antiarrhythmic therapy. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 1583-90 | 4 | 21 |
| 96 | The AFFORD clinical decision aid to identify emergency department patients with atrial fibrillation at low risk for 30-day adverse events. *American Journal of Cardiology*, **2015**, 115, 763-70 | 3 | 20 |
| 95 | Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 960-6 | 6.4 | 20 |
| 94 | ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. *Heart Rhythm*, **2009**, 6, 1327-32 | 6.7 | 20 |
| 93 | A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 636-41 | 2.7 | 20 |
| 92 | Variants in the SCN5A Promoter Associated With Various Arrhythmia Phenotypes. *Journal of the American Heart Association*, **2016**, 5, | 6 | 18 |
| 91 | Localization of the origin of arrhythmias for ablation: from Electrocardiography to advanced endocardial mapping systems. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 1309-25 | 2.7 | 18 |
| 90 | Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. *Europace*, **2014**, 16, 485-90 | 3.9 | 17 |
| 89 | Future of antiarrhythmic drugs. *Current Opinion in Cardiology*, **2006**, 21, 361-7 | 2.1 | 17 |
| 88 | Ion Channel and Structural Remodeling in Obesity-Mediated Atrial Fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2020**, 13, e008296 | 6.4 | 17 |
| 87 | Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. *Mayo Clinic Proceedings*, **2004**, 79, 1113-8 | 6.4 | 16 |
| 86 | Clinical use of and future perspectives on antiarrhythmic drugs. *European Journal of Clinical Pharmacology*, **2008**, 64, 1139-46 | 2.8 | 15 |

| | | | |
|---|---|---|---|
| 85 | Candidate gene approach to identifying rare genetic variants associated with lone atrial fibrillation. *Heart Rhythm*, **2014**, 11, 46-52 | 6.7 | 14 |
| 84 | The "missing" link in atrial fibrillation heritability. *Journal of Electrocardiology*, **2011**, 44, 641-4 | 1.4 | 14 |
| 83 | Genomics, heart failure and sudden cardiac death. *Heart Failure Reviews*, **2010**, 15, 229-38 | 5 | 14 |
| 82 | Implantable cardioverter-defibrillator malfunction due to mechanical failure of the header connection. *Journal of Cardiovascular Electrophysiology*, **2004**, 15, 1095-9 | 2.7 | 14 |
| 81 | Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. *Journal of Molecular and Cellular Cardiology*, **2019**, 132, 24-35 | 5.8 | 13 |
| 80 | A common variant on chromosome 4q25 is associated with prolonged PR interval in subjects with and without atrial fibrillation. *American Journal of Cardiology*, **2014**, 113, 309-13 | 3 | 13 |
| 79 | The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?. *Journal of Cardiovascular Pharmacology*, **2016**, 67, 9-18 | 3.1 | 13 |
| 78 | Association Between Family History and Early-Onset Atrial Fibrillation Across Racial and Ethnic Groups. *JAMA Network Open*, **2018**, 1, e182497 | 10.4 | 13 |
| 77 | Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. *Circulation: Arrhythmia and Electrophysiology*, **2020**, 13, e007676 | 6.4 | 12 |
| 76 | Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. *American Journal of Emergency Medicine*, **2013**, 31, 792-7 | 2.9 | 12 |
| 75 | A genotype-dependent intermediate ECG phenotype in patients with persistent lone atrial fibrillation genotype ECG-phenotype correlation in atrial fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 24-8 | 6.4 | 12 |
| 74 | Sympathetic activation enhances QT prolongation by quinidine. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 9-14 | 2.7 | 12 |
| 73 | A genome-wide association study to identify genomic modulators of rate control therapy in patients with atrial fibrillation. *American Journal of Cardiology*, **2014**, 114, 593-600 | 3 | 11 |
| 72 | Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. *Global Cardiology Science & Practice*, **2014**, 2014, 24-36 | 0.7 | 11 |
| 71 | Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals. *JAMA Cardiology*, **2021**, 6, 811-819 | 16.2 | 11 |
| 70 | Prevalence and predictors of atrial fibrillation among patients undergoing bariatric surgery. *Obesity Surgery*, **2014**, 24, 611-6 | 3.7 | 10 |
| 69 | Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza. *Heart Rhythm*, **2010**, 7, 1454-7 | 6.7 | 10 |
| 68 | On the relationship among QT interval, atrial fibrillation, and torsade de pointes. *Europace*, **2007**, 9 Suppl 4, iv1-3 | 3.9 | 10 |

| | | | |
|---|---|---|---|
| 67 | Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note. *Circulation: Cardiovascular Genetics*, **2015**, 8, 58-63 | | 9 |
| 66 | Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. *Cardiac Electrophysiology Clinics*, **2016**, 8, 481-93 | 1.4 | 9 |
| 65 | Atrial Fibrillation and Variants. *Cardiac Electrophysiology Clinics*, **2014**, 6, 741-748 | 1.4 | 9 |
| 64 | Severity of obstructive sleep apnea influences the effect of genotype on response to anti-arrhythmic drug therapy for atrial fibrillation. *Journal of Clinical Sleep Medicine*, **2014**, 10, 503-7 | 3.1 | 9 |
| 63 | Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. *Journal of Cardiology*, **2011**, 58, 124-30 | 3 | 9 |
| 62 | Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. *JAMA Cardiology*, **2021**, | 16.2 | 9 |
| 61 | Genetic modulation of atrial fibrillation risk in a Hispanic/Latino cohort. *PLoS ONE*, **2018**, 13, e0194480 | 3.7 | 8 |
| 60 | Investigating the Genetic Architecture of the PR Interval Using Clinical Phenotypes. *Circulation: Cardiovascular Genetics*, **2017**, 10, | | 7 |
| 59 | Is it time to develop a "pathogenicity" score to distinguish long QT syndrome causing mutations from "background" genetic noise?. *Heart Rhythm*, **2009**, 6, 1304-5 | 6.7 | 7 |
| 58 | Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome. *Circulation*, **2005**, 111, e161 | 16.7 | 6 |
| 57 | Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy. *Journal of Atrial Fibrillation*, **2010**, 3, 236 | 0.8 | 6 |
| 56 | Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs. *JAMA Cardiology*, **2020**, 5, 57-64 | 16.2 | 6 |
| 55 | Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation. *Stem Cell Reports*, **2021**, 16, 1542-1554 | 8 | 6 |
| 54 | Relation of Body Mass Index to Symptom Burden in Patients withAtrial Fibrillation. *American Journal of Cardiology*, **2018**, 122, 235-241 | 3 | 6 |
| 53 | Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data.. *Nature Genetics*, **2022**, | 36.3 | 6 |
| 52 | Genotype influence in responses to therapy for atrial fibrillation. *Expert Review of Cardiovascular Therapy*, **2016**, 14, 1119-31 | 2.5 | 5 |
| 51 | Genome-wide assessment for genetic variants associated with ventricular dysfunction after primary coronary artery bypass graft surgery. *PLoS ONE*, **2011**, 6, e24593 | 3.7 | 5 |
| 50 | Arrhythmia pharmacogenomics: methodological considerations. *Current Pharmaceutical Design*, **2009**, 15, 3734-41 | 3.3 | 5 |

| | | | |
|---|---|---|---|
| 49 | Recurrence of atrial tachyarrhythmias in implantable cardioverter-defibrillator recipients. *PACE - Pacing and Clinical Electrophysiology*, **2005**, 28, 1047-51 | 1.6 | 5 |
| 48 | Relation of Obstructive Sleep Apnea and a Common Variant at Chromosome 4q25 to Atrial Fibrillation. *American Journal of Cardiology*, **2017**, 119, 1387-1391 | 3 | 4 |
| 47 | Impact of traditional risk factors for the outcomes of atrial fibrillation across race and ethnicity and sex groups. *IJC Heart and Vasculature*, **2020**, 28, 100538 | 2.4 | 4 |
| 46 | Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. *PLoS ONE*, **2017**, 12, e0183690 | 3.7 | 4 |
| 45 | Triggers for cardiac events in patients with type 2 long QT syndrome. *Heart Rhythm*, **2010**, 7, 1806-7 | 6.7 | 4 |
| 44 | Cardiac sodium channel variants: action players with many faces. *Heart Rhythm*, **2008**, 5, 1441-3 | 6.7 | 4 |
| 43 | Congenital long QT syndrome aggravated by salt-wasting nephropathy. *Heart Rhythm*, **2005**, 2, 304-6 | 6.7 | 4 |
| 42 | Heart failure: a diagnostic and therapeutic dilemma in elderly patients. *Age and Ageing*, **1998**, 27, 539-43 | 3 | 4 |
| 41 | Can qualitative echocardiography be used to select patients for angiotensin-converting enzyme inhibitors following acute myocardial infarction?. *European Heart Journal*, **1996**, 17, 1783-6 | 9.5 | 4 |
| 40 | Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. *American Journal of Health-System Pharmacy*, **1996**, 53, 655-8 | 2.2 | 4 |
| 39 | Common genetic variants associated with obesity in an African-American and Hispanic/Latino population. *PLoS ONE*, **2021**, 16, e0250697 | 3.7 | 4 |
| 38 | Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation. *Journal of Arrhythmia*, **2016**, 32, 51-6 | 1.5 | 4 |
| 37 | Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children With Asthma. *Chest*, **2019**, 156, 1068-1079 | 5.3 | 3 |
| 36 | Multi-Ethnic Genome-Wide Association Study of Decomposed Cardioelectric Phenotypes Illustrates Strategies to Identify and Characterize Evidence of Shared Genetic Effects for Complex Traits. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002680 | 5.2 | 3 |
| 35 | Association of atrial fibrillation risk alleles and response to acute rate control therapy. *American Journal of Emergency Medicine*, **2016**, 34, 735-40 | 2.9 | 3 |
| 34 | GWAS of QRS duration identifies new loci specific to Hispanic/Latino populations. *PLoS ONE*, **2019**, 14, e0217796 | 3.7 | 3 |
| 33 | Attitudes of physicians in the treatment of congestive heart failure in older adults. *Journal of the American Geriatrics Society*, **1995**, 43, 943-4 | 5.6 | 3 |
| 32 | Abstract 4099: Genetic and Clinical Predictors of Response to Rate Control Therapy in Patients with Atrial Fibrillation. *Circulation*, **2008**, 118, | 16.7 | 3 |

| | | | |
|---|---|---|---|
| 31 | Pathogenic mutations perturb calmodulin regulation of Na1.8 channel. *Biochemical and Biophysical Research Communications*, **2020**, 533, 168-174 | 3.4 | 3 |
| 30 | Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.. *Science Advances*, **2022**, 8, eabl6579 | 14.3 | 3 |
| 29 | Standard Antiarrhythmic Drugs **2014**, 1095-1110 | | 2 |
| 28 | P1-84. *Heart Rhythm*, **2006**, 3, S135-S136 | 6.7 | 2 |
| 27 | Abstract 356: Loss of Function Mutations of Sodium Channel Beta-1 and Beta-2 Subunits Associated with Atrial Fibrillation and ST-segment Elevation. *Circulation*, **2007**, 116, | 16.7 | 2 |
| 26 | Clinical and Genetic Contributors to New-Onset Atrial Fibrillation in Critically Ill Adults. *Critical Care Medicine*, **2020**, 48, 22-30 | 1.4 | 2 |
| 25 | Bioengineering approaches to mature induced pluripotent stem cell-derived atrial cardiomyocytes to model atrial fibrillation. *Experimental Biology and Medicine*, **2021**, 246, 1816-1828 | 3.7 | 2 |
| 24 | Common genetic variation in circadian clock genes are associated with cardiovascular risk factors in an African American and Hispanic/Latino cohort. *IJC Heart and Vasculature*, **2021**, 34, 100808 | 2.4 | 2 |
| 23 | A new paradigm for predicting risk of Torsades de Pointes during drug development: Commentary on: "Improved prediction of drug-induced Torsades de Pointes through simulations of dynamics and machine learning algorithms". *Clinical Pharmacology and Therapeutics*, **2016**, 100, 324-6 | 6.1 | 2 |
| 22 | Mutant ANP induces mitochondrial and ion channel remodeling in a human iPSC-derived atrial fibrillation model.. *JCI Insight*, **2022**, 7, | 9.9 | 2 |
| 21 | Standard Antiarrhythmic Drugs **2018**, 1062-1075 | | 1 |
| 20 | Congenital right coronary artery aneurysm causing myocardial infarction, pseudoaneurysm formation, and right atrial compression. *Journal of the American Society of Echocardiography*, **2002**, 15, 736-8 | 5.8 | 1 |
| 19 | Localized aortic dissection: unusual features by transesophageal echocardiography. *Journal of the American Society of Echocardiography*, **2000**, 13, 1130-4 | 5.8 | 1 |
| 18 | Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed.. *Cell Genomics*, **2022**, 2, 100084-100084 | | 1 |
| 17 | Atrial Fibrillation Susceptibility Alleles on Chromosome 4q25 Modulate Response to Catheter Ablation. *Journal of Atrial Fibrillation*, **2010**, 3, 272 | 0.8 | 1 |
| 16 | Genetic and Molecular Basis of Arrhythmias **2011**, 65-86 | | 1 |
| 15 | Mutations in RPL3L and MYZAP increase risk of atrial fibrillation | | 1 |
| 14 | Atrial Fibrillation Genetic Risk Differentiates Cardioembolic Stroke from other Stroke Subtypes | | 1 |

| | | | |
|---|---|---|---|
| 13 | Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how?. *Cardiovascular Research*, **2021**, 117, 1718-1731 | 9.9 | 1 |
| 12 | Atrial Fibrillation in Inherited Channelopathies. *Cardiac Electrophysiology Clinics*, **2021**, 13, 155-163 | 1.4 | 0 |
| 11 | Assessment of the Framingham risk factors among ED patients with newly diagnosed atrial fibrillation. *American Journal of Emergency Medicine*, **2012**, 30, 151-7 | 2.9 | |
| 10 | Genomics of the Drug-Induced Long-QT Syndrome136-144 | | |
| 9 | Genomics and Atrial Arrhythmias65-79 | | |
| 8 | A shock in time. *Clinical Journal of Sport Medicine*, **2007**, 17, 497-9 | 3.2 | |
| 7 | Predicting ejection fraction after myocardial infarction. *Annals of Internal Medicine*, **1995**, 122, 729; author reply 730 | 8 | |
| 6 | Genetic and Molecular Basis of Cardiac Arrhythmias. *Contemporary Cardiology*, **2020**, 75-96 | 0.1 | |
| 5 | The Burden of Atrial Fibrillation in Sickle Cell Disease. *Blood*, **2021**, 138, 3119-3119 | 2.2 | |
| 4 | Algorithm to detect left ventricular dysfunction after myocardial infarction. Low specificity of algorithm would lead to extensive overtreatment. *BMJ: British Medical Journal*, **1996**, 312, 579-80 | | |
| 3 | RHYTHM DISORDERS **2009**, 367-387 | | |
| 2 | Atrial Fibrillation and Longitudinal Change in Cognitive Function in CKD. *Kidney International Reports*, **2021**, 6, 669-674 | 4.1 | |
| 1 | The Value of Rare Genetic Variation in the Prediction of Common Obesity in European Ancestry Populations.. *Frontiers in Endocrinology*, **2022**, 13, 863893 | 5.7 | |